8 unknown, 7 completed, 6 recruiting, 5 not yet recruiting. 12 Phase 2, 9 Phase 1, 4 Not applicable, 4 Phase 3, 2 Early Phase 1.
Follow Acute Graft-versus-Host Disease: new trials by email Literature Review of Acute Graft-versus-Host Disease trials Research Report on Acute Graft-versus-Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation 8-week Elastic Band Resistance Training Program - Hematologic Malignancies, Hematopoietic Stem Cell Transplantation | Not applicable | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 86 | 2026-10-12 | 2026-10-14 |
| Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD) Patient-Donor Derived Probiotics - Acute Graft-Versus-Host Disease | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2025-09-15 | 2025-09-23 |
| Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT) - Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 42 | 2025-09-01 | 2026-05-07 |
| A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation iMSC, conventional aGVHD prophylaxis - Acute Graft-versus-Host Disease | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 56 | 2025-06-01 | 2025-04-29 |
| MAGIC Ruxolitinib for aGVHD Ruxolitinib, Methylprednisolone - Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation | Phase 2 | Recruiting | John Levine | 98 | 2025-05-14 | 2026-03-23 |
| A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD NCR102 injection - Acute Graft-versus-Host Disease | Phase 1 / Phase 2 | Not yet recruiting | Nuwacell Biotechnologies Co., Ltd. | 24 | 2025-04-28 | 2025-04-23 |
| Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection - Acute Graft-versus-Host Disease | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 174 | 2025-03-03 | 2025-08-08 |
| Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease RUX+Steroids - Acute Graft-versus-host Disease | Phase 1 | Active not recruiting | Daihong Liu | 30 | 2025-01-17 | 2026-06-15 |
| Universal CNK-UT Therapy for Refractory aGVHD Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) - Acute Graft-versus-Host Disease | Phase 1 | Recruiting | First Affiliated Hospital of Zhejiang University | 23 | 2024-12-14 | 2024-12-27 |
| A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Jaktinib Hydrochloride Tablets - Acute Graft-Versus-Host Disease | Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 60 | 2024-12-01 | 2024-03-06 |
| Tissue-resident Immune Cell Subsets in aGVHD Acute Graft-versus-Host Disease, Hematopoietic Stem Cell Transplantation | Recruiting | Nanfang Hospital, Southern Medical University | 40 | 2024-11-16 | 2024-11-27 | |
| A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation bacillus coagulans combined with the best treatment options for preventing aGVHD, BAT - Acute Graft-versus-host Disease | Not applicable | Unknown | Yamin Fan | 286 | 2024-09-27 | 2024-09-25 |
| A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD. AC-003 - Acute Graft-versus-Host Disease | Phase 1 | Completed | Accro Bioscience (Suzhou) Limited | 4 | 2024-07-25 | 2026-10-28 |
| Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI PDCy, Non Cy - Acute Graft-versus-host Disease | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 66 | 2024-07-01 | 2024-07-08 |
| Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases Time of stem cell infusion - Acute Graft-versus-host Disease | Phase 3 | Recruiting | Anhui Provincial Hospital | 198 | 2024-03-15 | 2026-08-24 |
| Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Time of stem cell infusion - Acute Graft-versus-host Disease | Phase 3 | Active not recruiting | Anhui Provincial Hospital | 198 | 2024-03-01 | 2025-12-31 |
| Donor Neutrophil Subsets to Predict the Risk of aGVHD Acute Graft-versus-Host Disease | Unknown | Nanfang Hospital, Southern Medical University | 260 | 2023-12-01 | 2024-05-01 | |
| A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) GDC-8264 - Acute Graft-versus-host Disease | Phase 1 | Completed | Genentech, Inc. | 7 | 2023-04-06 | 2025-05-28 |
| Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT Acute Graft-versus-host Disease | Completed | IRCCS Burlo Garofolo | 28 | 2022-03-10 | 2023-04-24 | |
| Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Efmarodocokin Alfa - Acute Graft-versus-host Disease | Phase 1 | Completed | Genentech, Inc. | 18 | 2020-11-19 | 2024-04-11 |
Showing 20 of 33. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (3) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neutropenia (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Stomatitis (1)
Immune System Diseases (5) · Bronchial Diseases (3) · Bronchiolitis (3) · Bronchiolitis Obliterans (3) · Bronchitis (3) · Graft vs Host Disease (3) · Lung Diseases (3) · Lung Diseases, Obstructive (3) · Organizing Pneumonia (3) · Respiratory Tract Diseases (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Agranulocytosis (1)
Methylprednisolone (3) · Adrenal Cortex Hormones (2) · INCB039110 (2) · itacitinib (2) · Blood Specimen Collection (1) · Calcineurin Inhibitors (1) · Eosinophil Cationic Protein (1) · Fecal Microbiota Transplantation (1) · Interleukin-2 (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Moxibustion (1) · PC61 monoclonal antibody (1) · Prednisone (1) · Sirolimus (1)
Nanfang Hospital, Southern Medical University (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · Anhui Provincial Hospital (2) · Genentech, Inc. (2) · Incyte Corporation (2) · Accro Bioscience (Suzhou) Limited (1) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Alexion Pharmaceuticals, Inc. (1) · Daihong Liu (1) · Fate Therapeutics (1) · First Affiliated Hospital of Zhejiang University (1) · IRCCS Burlo Garofolo (1) · John Levine (1) · Mallinckrodt (1) · Nuwacell Biotechnologies Co., Ltd. (1)
China (15) · United States (9) · France (3) · Italy (3) · Belgium (2) · Germany (2) · United Kingdom (2) · Australia (1) · Austria (1) · Canada (1) · Japan (1) · Netherlands (1) · South Korea (1) · Spain (1) · Switzerland (1)
Hua Jin (2) · Rodica Morariu-Zamfir, MD (2) · Xiaoyu Zhu, ph.D (2) · Alessandra Maestro, PharmD (1) · Dai-Hong Liu, Dr. (1) · Eynav Klechevsky, Ph.D. (1) · Han-Wei Su (1) · Hannah Choe, MD (1) · He Huang, PHD (1) · John Levine, MD, MS (1) · Qifa Liu (1) · Qifa Liu, MD (1) · Sarah Cooley, MD (1)
PMID 10091805, PMID 17008536, PMID 17573453, PMID 18322708, PMID 18619375, PMID 20953908, PMID 22050904, PMID 22461866, PMID 22776268, PMID 23485478, PMID 23954992, PMID 24179471, PMID 25299140, PMID 25386344, PMID 25445023, PMID 25728366, PMID 26061092, PMID 26169616, PMID 26345187, PMID 26473759, PMID 28042020, PMID 28061985, PMID 28253393, PMID 28458705, PMID 28621019, PMID 28670114, PMID 28688533, PMID 28915856, PMID 29171820, PMID 29313949, PMID 29336645, PMID 29506345, PMID 29626261, PMID 30165140, PMID 30191843, PMID 30461314, PMID 30725636, PMID 31302766, PMID 31541205, PMID 31626055, PMID 32058362, PMID 32132841, PMID 32303764, PMID 32457216, PMID 32519831, PMID 32524098, PMID 32560160, PMID 32652612, PMID 33120223, PMID 33162898
2018 (1), P01CA039542 (1)